Progen Co Ltd
296160
Company Profile
Business description
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.
Contact
172 Magokjungang-ro
7th Floor, Bio Innovation Park
Gangseo-gu
Seoul
KORT: +82 260982800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
50
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,960.20 | 3.30 | -0.04% |
| CAC 40 | 7,800.88 | 33.70 | -0.43% |
| DAX 40 | 23,970.36 | 247.14 | -1.02% |
| Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
| FTSE 100 | 9,081.44 | 38.87 | -0.43% |
| HKSE | 25,354.69 | 207.44 | -0.81% |
| NASDAQ | 21,178.58 | 70.27 | 0.33% |
| Nikkei 225 | 40,628.99 | 369.28 | -0.90% |
| NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
| S&P 500 | 6,389.77 | 1.13 | 0.02% |
| S&P/ASX 200 | 8,698.80 | 1.10 | 0.01% |
| SSE Composite Index | 3,602.28 | 4.34 | 0.12% |